Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$95.71 -4.5%	$97.44	$76.53 ▼ $131.49	$23.01B	1.35	913,559 shs	1.49 million shs
ONC Beigene	$246.04 -0.3%	$239.92	$141.31 ▼ $287.88	$24.48B	0.35	458,911 shs	406,953 shs
RVMD Revolution Medicines	$39.98 +2.3%	$37.56	$29.17 ▼ $62.40	$7.45B	1.11	1.52 million shs	2.62 million shs
TEVA Teva Pharmaceutical Industries	$16.77 -4.3%	$15.52	$12.47 ▼ $22.80	$19.01B	0.62	10.12 million shs	19.85 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-4.53%	-3.01%	-8.10%	-15.24%	+2.66%
ONC Beigene	-0.26%	+1.91%	-5.30%	-9.48%	+24,603,999,900.00%
RVMD Revolution Medicines	+2.30%	+0.53%	-0.99%	-1.87%	+6.02%
TEVA Teva Pharmaceutical Industries	-4.63%	-1.03%	+8.12%	+1.95%	+1.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.6494 of 5 stars	4.4	2.0	0.0	0.0	3.1	0.8	0.0
ONC Beigene	3.0933 of 5 stars	4.5	0.0	0.0	0.0	2.3	1.7	0.6
RVMD Revolution Medicines	4.2736 of 5 stars	4.5	0.0	0.0	4.7	3.5	2.5	0.0
TEVA Teva Pharmaceutical Industries	2.6988 of 5 stars	3.6	3.0	0.8	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$140.14	46.43% Upside
ONC Beigene	3.00	Buy	$319.00	29.65% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	67.79% Upside
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.50	46.09% Upside

Current Analyst Ratings Breakdown

Latest RVMD, ONC, BNTX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $134.00
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	8.38	$4.12 per share	23.25	$92.17 per share	1.04
ONC Beigene	$4.18B	5.85	N/A	N/A	$37.10 per share	6.63
RVMD Revolution Medicines	$742K	10,036.38	N/A	N/A	$11.09 per share	3.61
TEVA Teva Pharmaceutical Industries	$16.62B	1.14	$3.32 per share	5.05	$4.75 per share	3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	$1.01B	-$3.40	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	8/4/2025 (Estimated)
ONC Beigene	-$881.71M	-$3.72	N/A	346.54	7.73	-25.94%	-25.12%	-14.95%	N/A
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.38	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest RVMD, ONC, BNTX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ONC Beigene	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.60%	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.03%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.33	7.21
ONC Beigene	0.05	1.93	1.72
RVMD Revolution Medicines	N/A	14.24	14.24
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
ONC Beigene	48.55%
RVMD Revolution Medicines	94.34%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
ONC Beigene	6.62%
RVMD Revolution Medicines	8.20%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	3,080	240.39 million	193.71 million	Optionable
ONC Beigene	9,000	99.25 million	90.59 million	N/A
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

RVMD, ONC, BNTX, and TEVA Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress

May 31 at 12:49 PM | insidermonkey.com

Zacks Research Issues Positive Outlook for TEVA Earnings

May 31 at 5:52 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Centaurus Financial Inc.

May 31 at 4:51 AM | marketbeat.com

Siemens Fonds Invest GmbH Invests $611,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 31 at 4:43 AM | marketbeat.com

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30 at 9:05 PM | globenewswire.com

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

May 30 at 9:00 PM | globenewswire.com

Teva Gets High Court Extension to Challenge Orange Book Ruling

May 30 at 5:47 PM | news.bloomberglaw.com

Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 4% - Should You Sell?

May 30 at 2:30 PM | marketbeat.com

FDA Grants Fast Track Designation to Teva Celiac Disease Candidate

May 30 at 12:45 PM | pharmtech.com

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by Truist Financial

May 30 at 7:49 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by California State Teachers Retirement System

May 30 at 5:52 AM | marketbeat.com

Truist Financial Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

May 30 at 1:51 AM | americanbankingnews.com

Teva gives aggressive guidance for innovative drugs

May 29 at 4:24 PM | en.globes.co.il

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

May 29 at 4:24 PM | msn.com

Truist Securities Initiates Coverage of Teva Pharmaceutical Industries Limited - Depositary Receipt () (TEVA) with Buy Recommendation

May 29 at 11:23 AM | msn.com

Teva Reaffirms 2027 Targets, Aims for 30% Operating Margin

May 29 at 11:23 AM | msn.com

Teva Pharmaceutical Industries (NYSE:TEVA) Earns Buy Rating from Analysts at Truist Financial

May 29 at 10:06 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. Announces Acceleration Plan to Transform into a Leading Biopharma Company by 2030

May 29 at 8:32 AM | quiverquant.com

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 29 at 8:00 AM | globenewswire.com

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

May 28 at 12:11 PM | zacks.com

FDA fast-tracks Teva's coeliac disease treatment

May 28 at 8:33 AM | pharmaphorum.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
By Leo Miller | May 27, 2025
View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
Turbulence for Joby Shares: What's Behind the Recent Dip?
By Jeffrey Neal Johnson | May 22, 2025
View Turbulence for Joby Shares: What's Behind the Recent Dip?
Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
By Chris Markoch | May 2, 2025
View Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
Joby Just Flew Two Aircraft at Once—Here’s Why It Matters
By Jeffrey Neal Johnson | May 14, 2025
View Joby Just Flew Two Aircraft at Once—Here’s Why It Matters
Advance Auto Parts: Did Earnings Defuse Tariff Concerns?
By Gabriel Osorio-Mazilli | May 28, 2025
View Advance Auto Parts: Did Earnings Defuse Tariff Concerns?

RVMD, BNTX, ONC, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$95.71 -4.54 (-4.53%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$96.12 +0.42 (+0.43%)

As of 05/30/2025 07:56 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Beigene NASDAQ:ONC

$246.04 -0.64 (-0.26%)

As of 05/30/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Revolution Medicines NASDAQ:RVMD

$39.98 +0.90 (+2.30%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$38.40 -1.58 (-3.95%)

As of 05/30/2025 05:59 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Teva Pharmaceutical Industries NYSE:TEVA

$16.77 -0.76 (-4.34%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$16.77 +0.00 (+0.03%)

As of 05/30/2025 07:54 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time